Cargando…

In-silico comparison of two induction regimens (7 + 3 vs 7 + 3 plus additional bone marrow evaluation) in acute myeloid leukemia treatment

BACKGROUND: Clinical integration of systems biology approaches is gaining in importance in the course of digital revolution in modern medicine. We present our results of the analysis of an extended mathematical model describing abnormal human hematopoiesis. The model is able to describe the course o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banck, Jan Christoph, Görlich, Dennis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357450/ https://www.ncbi.nlm.nih.gov/pubmed/30704476 http://dx.doi.org/10.1186/s12918-019-0684-0

Ejemplares similares

The “7+3” regimen in acute myeloid leukemia
por: Rowe, Jacob M.
Publicado: (2022)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

Frequency of complete remission after standard 3+7 induction therapy in patients with acute myeloid leukemia
por: Shireen, Iram, et al.
Publicado: (2022)

P516: CARDIOTOXICITY OF CPX-351 VS 7 + 3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA
por: Mitchell, Joshua D., et al.
Publicado: (2023)

Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia
por: Yoon, Jae-Ho, et al.
Publicado: (2017)

Chemoresponse of de novo Acute Myeloid Leukemia to “7+3” Induction can Be Predicted by c-Myc-facilitated Cytogenetics
por: Hsiao, Tzu-Hung, et al.
Publicado: (2021)

A Phase I Trial of Sirolimus with “7&3” Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia
por: Palmisiano, Neil, et al.
Publicado: (2023)

B7‐H3 protein expression in acute myeloid leukemia
por: Guery, Thomas, et al.
Publicado: (2015)

The effectiveness of three different 7 + 3 induction regimes in China: A retrospective analysis in adult patients with acute myeloid leukemia
por: Lin, Peng, et al.
Publicado: (2021)

Association of leukocyte nadir with complete remission in Indonesian acute myeloid leukemia patients undergoing 7+3 remission induction chemotherapy
por: Hadisantoso, Dwi Wahyunianto, et al.
Publicado: (2022)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
por: Tormo, Mar, et al.
Publicado: (2023)

Low-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia
por: Vey, Norbert
Publicado: (2020)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
por: Liu, Qingguo, et al.
Publicado: (2020)

Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data
por: Othus, Megan, et al.
Publicado: (2022)

Expression characteristic of 4Ig B7-H3 and 2Ig B7-H3 in acute myeloid leukemia
por: Zhang, Wei, et al.
Publicado: (2021)

EZH2 Mutations Are Related to Low Blast Percentage in Bone Marrow and -7/del(7q) in De Novo Acute Myeloid Leukemia
por: Wang, Xiuli, et al.
Publicado: (2013)

7-Ketocholesterol Promotes Oxiapoptophagy in Bone Marrow Mesenchymal Stem Cell from Patients with Acute Myeloid Leukemia
por: Paz, Jessica Liliane, et al.
Publicado: (2019)

Venetoclax-containing regimens in acute myeloid leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2021)

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Zeidan, Amer M, et al.
Publicado: (2023)

Evaluation of bone marrow aspirates in patients with acute myeloid leukemia at day 14 of induction therapy
por: Souto Filho, João Tadeu D, et al.
Publicado: (2015)

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
por: Lee, Lauren Y., et al.
Publicado: (2021)

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
por: Daver, Naval, et al.
Publicado: (2022)

PB1854: EARLY SEVERE ADVERSE EVENTS OF ACUTE MYELOID LEUKEMIA THERAPY DEPENDING ON THE INDUCTION THERAPY REGIMEN
por: Mikhailov, Evgeniy, et al.
Publicado: (2023)

Expression and prognosis of the B7 family in acute myeloid leukemia
por: Zhang, Wei, et al.
Publicado: (2021)

Transformation of Acute Myeloid Leukemia with Deletion of Chromosome 7q and Additional Abnormalities in Chromosome 8 in a Patient with Essential Thrombocythemia
por: Shimizu, Ayaka, et al.
Publicado: (2021)

Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia
por: Wobus, Manja, et al.
Publicado: (2015)

P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY
por: Ritchie, Ellen, et al.
Publicado: (2023)

Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re‐induction chemotherapy
por: Ruan, Min, et al.
Publicado: (2021)

Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia
por: Zhang, Ye, et al.
Publicado: (2016)

A Case Report: Acute Myeloid Leukemia (FAB M7)
por: Masoumi-Dehshiri, R, et al.
Publicado: (2014)

BCL7A is silenced by hypermethylation to promote acute myeloid leukemia
por: Patiño-Mercau, Juan Rodrigo, et al.
Publicado: (2023)

GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia
por: Xiao, Xinhua, et al.
Publicado: (2023)

Differential regulation of myeloid leukemias by the bone marrow microenvironment
por: Krause, Daniela S., et al.
Publicado: (2013)

The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia
por: Pimenta, Débora Bifano, et al.
Publicado: (2021)

Predictive value of integrin α7 for acute myeloid leukemia risk and its correlation with prognosis in acute myeloid leukemia patients
por: Zeng, Mingyue, et al.
Publicado: (2019)

Integrated analysis reveals distinct molecular, clinical, and immunological features of B7‐H3 in acute myeloid leukemia
por: Zhang, Ling‐yi, et al.
Publicado: (2021)

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”
por: Begna, K. H., et al.
Publicado: (2022)

Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype
por: Baron, Frédéric, et al.
Publicado: (2019)

Successful Outcomes of Children Simultaneously Diagnosed with Acute Myeloid Leukemia and Covid-19: The Role of a Mild Chemotherapeutic Induction Regimen
por: Lins, Mecneide Mendes, et al.
Publicado: (2020)

Subclones of bone marrow CD34(+) cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy
por: Jia, Ruinan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kh2mft13jclr7rig1rfabco1dm